Introduction {#s1}
============

Upon sensing invading viruses, host cells produce type I interferons (IFNs), leading to the expression of an array of IFN-stimulated genes (ISGs). This first-line response suppresses viral spread by generating an antiviral state within host cells, and supports the initiation of adaptive immunity ([@bib20]). Viral sensing may involve non-hematopoietic or hematopoietic cells that are targets of infection. Specific pathogen-associated motifs, such as viral nucleic acids, are recognized by pattern recognition receptors, which can be cytoplasmic (e.g. retinoic inducible gene-I (RIG-I)-like receptors, and NOD-like Receptors) or endosomal (e.g. Toll-like receptors; TLRs) ([@bib24]). Due to the potency of these innate responses, most viruses have evolved mechanisms to subvert or evade pathogen-sensing pathways ([@bib14]).

We and others have recently highlighted the existence of alternative or indirect pathogen-sensing mechanisms that circumvents cell-intrinsic viral evasion mechanisms ([@bib47]). Such alternative pathways involve the sensing of infected target cells by plasmacytoid dendritic cells (pDCs), a DC subtype specialized in the production of robust level of type I IFNs (referred herein to as IFN-I) ([@bib41]). Notably, this was illustrated in the context of dengue virus (DENV), a positive-sense single-stranded RNA virus, which represents global health concerns ([@bib1]). Recent in vitro work highlighted a newly defined mode of pDC activation, which is mediated primarily by non-infectious immature DENV particles and requires physical cell-cell contact with DENV-infected cells ([@bib10]). Importantly, such cell-cell contact-dependent activation of pDCs has also been reported for several other genetically distant viruses ([@bib47]). Consistently, DENV, like some other viruses, does not to directly infect pDCs ([@bib10]; [@bib47]). We thus aimed to test how such indirect cell-cell sensing of viral pathogens by pDCs, in the absence of pDC infection, engages host mechanisms for in vivo viral clearance.

pDCs function as sentinels of viral infection, predominantly via recognition of single-stranded RNA and unmethylated CpG containing DNA by endosomal TLR7 and TLR9, respectively. Activation of TLR7 or TLR9 results in copious secretion of IFN-I as well as other proinflammatory cytokines (notably TNFα), driven by the transcription factor(s) interferon regulatory factor (IRF)−7 and nuclear factor-kappa B (NF-κB), respectively ([@bib41]). Interestingly, despite the inherent ability of pDCs to produce both IFN-I and NF-κB-induced cytokines, previous studies have suggested a 'bifurcated' pattern of TLR7/9 signaling, where IFN-I production may occur in the absence of NF-κB activation, and vice versa ([@bib41]). The production of IFN-I or pro-inflammatory cytokines may in part be dependent on the sub-cellular compartment in which these TLRs encounter activating signal, as CpG-A accumulates in early endosomes to induce IFN-I whereas CpG-B aggregates in endolysosomes to activate NF-κB ([@bib41]). In the context of viral infection, pDCs exposed to cell-associated Hepatitis C virus produced IFN-I but not NF-κB-dependent cytokines ([@bib9]). Despite these observations, the consequences of pDC IFN-I production in the absence of NF-κB induction remain unclear, and have not yet been shown to be sufficient for in vivo viral control.

Herein, we show that indirect activation of pDCs by contact with DENV or CHIKV infected cells results in an IRF7-induced IFN response, in the absence of NF-κB inflammatory responses. We developed a novel mouse model where *Irf7* expression is pDC-restricted, that is, *Irf3^-/-^;Irf7^-/-^* double knockout mice, with *Irf7* expression driven under the pDC-specific promoter *Sialic acid binding Ig-like lectin H* (*Siglech*) ([@bib2]; [@bib44]; [@bib48]). We demonstrated that pDC-restricted IRF7-induced signaling is sufficient to achieve in vivo control of DENV and CHIKV infections. We further elucidated that the early pDC IRF7-mediated response accelerates type II IFN (IFNγ) responses via natural killer (NK) cell activation, thus positioning pDCs as a cell type that regulates the interplay between type I and type II IFN responses in the control of these viral infections, an immune axis that is independent of other sources of type I IFN or pDC-derived NF-κB-induced cytokines.

Results {#s2}
=======

Cell-cell sensing of DENV-infected cells does not induce inflammatory NF-κB responses by pDCs {#s2-1}
---------------------------------------------------------------------------------------------

We previously reported that ex vivo activation of an antiviral response by pDCs requires physical contact with DENV-infected cells ([@bib10]). Prior studies suggested that pDC TLR7/9 signaling differentially induced IRF7 and/or NF-κB, depending on the ligand ([@bib41]). Thus, we determined relative pDC secretion of representative NF-κB-induced (TNFα) and IRF7-induced (IFNα) cytokines in response to DENV. The sensing of DENV-infected cells by human pDCs failed to induce TNFα secretion ([Figure 1A](#fig1){ref-type="fig"}). This was in contrast to the robust TNFα production triggered by direct TLR7 stimuli, including the synthetic ligand imiquimod (IMQ) and influenza A \[Flu\], which directly activates pDCs as cell-free virus as previously reported ([@bib10]) ([Figure 1A](#fig1){ref-type="fig"}).

pDC activation by DENV, the result of cell-cell transfer of TLR7 ligands, may occur more slowly than direct activation by cell-free stimuli. To assess if differential kinetics of pDC activation underlie the difference in TNFα production, we evaluated pre-treatment of human pDCs with low-dose IFNβ, prior to coculture with infected cells. Such pre-treatment regimens have been previously shown to accelerate both IFNα and TNFα production in response to influenza virus ([@bib30]). While IFNβ pretreatment accelerated the kinetics of pDC-derived IFNα (all stimuli) and TNFα production (IMQ/Flu), we observed minimal TNFα production in response to DENV-infected cells ([Figure 1B](#fig1){ref-type="fig"}). These observations imply that the defect in DENV-mediated TNFα induction by pDCs might be due to the indirect mechanism of stimulation. Furthermore, we showed that pDC TNFα levels in response to IMQ were not diminished in presence of DENV-infected cells ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Together, these results indicated that DENV is neither promoting nor preventing the activation of NF-κB-induced TNFα production by pDCs.

![Lack of NF-κB response by pDCs in ex vivo coculture with DENV infected cells.\
(**A**) Quantification of IFNα and TNFα in supernatants of human pDCs cocultured with DENV-infected (DENV cells) or uninfected BHK-21 cells (Mock), in presence of synthetic TLR7 agonist: Imiquimod; IMQ; 1 µg/mL or influenza infectious supernatant; Flu; 3 × 10^3^ FFU. (**B**) pDCs were pretreated for 3 hr with low-dose IFNβ (50 U/mL) and then cocultured or treated as in (**A**). Median, *n* = 3 independent experiments. (**C--D**) qRT-PCR analysis of gene expression (using mouse-specific primers) by WT murine splenic pDCs cocultured for 22 hr with uninfected- (mock cells) or DENV-infected Huh7.5.1 cells (DENV cells) or treated with TLR7/8 agonist (R848). Expression levels are normalized to housekeeping genes (*β-actin*) and shown as Z scores (red-blue gradient from maximum to minimum expression).](elife-34273-fig1){#fig1}

We extended these findings to mouse pDC activation, utilizing cells derived from either bone marrow (BM) or isolated from spleen. We also assessed a broader range of NF-κB-dependent genes. DENV-infected cells induced higher levels of IFNα and interferon-stimulated genes (ISGs) as compared to synthetic TLR7/8 agonists (R848 and IMQ) ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C--D](#fig1s1){ref-type="fig"}), results that were consistent with human pDC findings ([Figure 1A--B](#fig1){ref-type="fig"}). Conversely, the TLR7/8 agonist R848 induced a strong NF-κB-dependent gene signature in mouse pDCs, whereas limited induction was observed when using DENV-infected cells ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Together, these results demonstrated that pDC-mediated sensing of DENV-infected cells primarily leads to IFN-I production and a strong ISG response in the absence of NF-κB-mediated inflammatory responses.

An in vivo model for pDC-restricted IFN-I production {#s2-2}
----------------------------------------------------

To address how this IRF7- and IFN-I-restricted response to DENV may position pDCs as critical in the control of viral infections, we generated a unique mouse model where IRF7 signaling is restricted to pDCs. We established a knock-in strain where *Irf7* expression is driven by the pDC-specific *Siglech* promoter (thus called *Siglech^Irf7/+^*) ([Figure 2A](#fig2){ref-type="fig"}). We next backcrossed these mice onto *Irf3^-/-^;Irf7^-/-^* double knockout mice to generate hemizygous *Irf7*-expressing animals (*Siglech^Irf7/+^;Irf3^-/-^;Irf7^-/-^* referred to as 'pDC:Irf7^+^' mice). Use of hemizygous mice preserved one copy of the *Siglech* gene ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Irf3/7 double knockout mice (referred to as Irf3/7 DKO mice), deficient in IFN-I production ([@bib34]; [@bib35]) were used as comparator negative controls in all experiments.

![Functional validation of the pDC:Irf7^+^mouse model.\
(**A**) Targeting construct for the knock-in of *irf7* under the control of the *siglech* promoter. (**B**) Expression levels of IRF7 analyzed by FACS in pDCs and non-pDC DCs isolated from spleens of uninfected WT, Irf3/7 DKO and pDC:Irf7^+^ mice. Gating strategy for DCs and pDCs from splenocyte populations (upper panels), IRF7 expression (lower panels); 3--5 mice per condition. (**C--D**) Quantification of IFN activity by bioassay in plasma (**C**) and spleen homogenates (**D**) at various time-points post-injection of mice with agonists of TLR3 and TLR9, polyinosinic:polycytidylic acid (poly I:C) and CpG-type A oligodeoxynucleotides (CpG), respectively; median, *n* = 3--5 mice per condition. (**E**) Quantification of IFNα and TNFα in ex vivo cultures of pDCs (mPDCA1^+^ cells) isolated from BM of WT, Irf3/7 DKO and pDC:Irf7^+^ mice and treated for 22 hr with TLR7/8 agonist (R848) or influenza virus infectious supernatant (Flu); median, *n* = 3--5 mice per condition.](elife-34273-fig2){#fig2}

To validate the *Irf7* knock-in in pDC:Irf7^+^ mice, we analyzed IRF7 protein levels in DC subsets. pDCs were the only cell type to retain significant levels of IRF7 protein expression, seen in both pDC:Irf7^+^ and WT mice, but not in Irf3/7 DKO mice ([Figure 2B](#fig2){ref-type="fig"}). To functionally validate the pDC:Irf7^+^ mice, we assessed IFN-I activity induced upon in vivo treatment with agonists of TLR9 and TLR3, which are expressed or not by pDCs, respectively ([@bib41]). As expected, we observed IFN-I activity in plasma/spleen of WT mice stimulated by either agonist, whereas little-to-no IFN-I activity was detected in Irf3/7 DKO mice ([Figure 2C--D](#fig2){ref-type="fig"}). Consistent with the TLR expression patterns in pDCs ([@bib41]), pDC:Irf7^+^ mice produced high levels of IFN-I in response to TLR9, but not TLR3 agonists.

Using this model system, we assessed how pDC IRF7-signaling mediates antiviral responses to DENV. First, we purified pDCs from WT, Irf3/7 DKO and pDC:Irf7^+^ mice, and treated them with TLR7 agonists (R848/IMQ/cell-free Flu) or DENV-infected cells. pDC:Irf7^+^ and WT pDCs produced similar amounts of IFNα ([Figures 2E](#fig2){ref-type="fig"} and [3A](#fig3){ref-type="fig"}), confirming the functionality of IRF7 signaling in pDC:Irf7^+^ mice. We also tested NF-κB-signaling in pDCs from Irf3/7 DKO and pDC:Irf7^+^ mice induced by the same TLR7 agonists. Confirming independent activation of NF-κB, we observed TNFα secretion levels in both strains to be comparable to WT mice ([Figures 2F](#fig2){ref-type="fig"} and [3B](#fig3){ref-type="fig"}). Of note, ISGs previously defined as IRF5-dependent (e.g. *Mx1, Ifit1*) ([@bib28]) were still upregulated in Irf3/7 DKO pDCs when cocultured with DENV-infected cells or stimulated by other TLR7 agonists ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

![pDCs respond in vivo to DENV in a TLR7/IRF7 but not an NF-κB-dependent manner.\
(**A--B**) Quantification of IFNα (**A**) and TNFα (**B**) by ELISA in ex vivo culture supernatants of pDCs isolated from BM of WT, Irf3/7 DKO and pDC:Irf7^+^ mice and treated for 22 hr with DENV infectious supernatant (DENV SN), TLR7 agonist (IMQ and flu, 3 × 10^2^ ffu), or cocultured with DENV-infected Huh7.5.1 cells ± TLR7 inhibitor IRS661; median, *n = 3--5* independent experiments. (**C--G**) Intravenous (i.v.) DENV infection followed by the analysis of IFNα and gene expression in organs collected at the indicated time points p.i. (**C--D**) Quantification of IFNα in spleen homogenates and plasma by ELISA; median; each data point corresponds to an individual mouse: *n* = 5--6 and n = 3 mice per condition, for spleen and plasma samples, respectively. IFNα was undetectable in uninfected control mice. (**E--G**) qRT-PCR analysis of gene expression in the indicated tissues at 18 hr (**E**) and 24 hr (**F--G**) p.i., and normalized to housekeeping panel (*hprt1*, *β-actin*, *18S*). Expression levels shown as Z scores, *n* = 2 (**E**) or 3 (**F--G**) infected and *n* = 1 (**E**) or 2 (**F--G**) uninfected mice per genotype.](elife-34273-fig3){#fig3}

pDC-IRF7-induced potent downstream ISG responses in absence of detectable IFN-I {#s2-3}
-------------------------------------------------------------------------------

To determine whether IFN-I response to viral stimuli was restored in pDC:Irf7^+^ mice, animals were infected with DENV systemically (intravenously, i.v.), and IFNα/β expression was assessed. High levels of IFNα were detected in both the spleen and plasma of infected WT mice ([Figure 3C--D](#fig3){ref-type="fig"}), but not Irf3/7 DKO mice, in agreement with previous results ([@bib4]). IFNβ levels displayed the same pattern of expression (data not shown). pDC:Irf7^+^ mice had undetectable IFNα/β levels in both the plasma and spleen at all analyzed times post-infection (p.i.) ([Figure 3C--D](#fig3){ref-type="fig"}).

We considered the possibility that the pDC response to DENV may occur in a localized manner, with insufficient type I IFN in plasma or spleen to allow its detection. We thus assessed downstream responses of IFNα/β receptor (IFNAR) signaling via qRT-PCR analysis of ISGs in different tissues of DENV-infected mice. The ISGs (*Ifit1, Usp18*, and *Ifit3*) were selected for their robust expression following by IFN-I stimulation, as compared to type II IFN ([@bib29]). Importantly, despite undetectable IFNα/β in DENV-infected pDC:Irf7^+^ mice, an early induction (i.e. 18 h p.i.) of *ISG* RNAs was observed in all tissues analyzed. By contrast, this early induction was not observed in Irf3/7 DKO mice ([Figure 3E](#fig3){ref-type="fig"}). Of note, basal *ISG* expression levels were lower in Irf3/7 DKO and pDC:Irf7^+^ mice compared to WT, likely reflecting diminished basal IFNAR signaling in the absence of *Irf3* and *Irf7* ([@bib17]). These results indicate that restricted expression of *Irf7* in pDCs is sufficient to generate a systemic ISG response.

In vivo activation of pDC IRF7 antiviral signaling is sufficient to control DENV infection {#s2-4}
------------------------------------------------------------------------------------------

The pDC:Irf7^+^ model provided a means to distinguish, in vivo, the role of pDCs in regulating antiviral IFN-I-mediated versus NF-κB-induced response(s) to DENV infection. We therefore measured IRF/STAT-dependent *ISG* expression in multiple organs, and a larger panel of ISGs and NF-κB-dependent transcripts in the liver of DENV-infected animals. DENV infection induced *ISGs* and NF-κB-dependent transcripts in WT, but not Irf3/7 DKO mice ([Figure 3E--G](#fig3){ref-type="fig"}; expressed as magnitude-independent Z score and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; expressed as magnitude-dependent fold-change), confirming previous findings ([@bib4]). Strikingly, despite a strong upregulation of ISGs in DENV-infected pDC:Irf7^+^ mice, we observed minimal induction of NF-κB-dependent inflammation-related transcripts ([Figure 3F--G](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Based on these in vivo and ex vivo observations, we concluded that the principal signaling pathway downstream of DENV-activated pDCs is IRF7-dependent induction of the IFN-I pathway, which could be wholly segregated from the activation of NF-κB-induced cytokines.

We next sought to determine whether pDC IRF7-induced responses are sufficient to protect mice from DENV. Mice were infected i.v. by DENV and viral RNA and titers were assessed in the spleen, the primary site of replication in infected mice. Viral titer and RNA levels were lower in WT mice than either Irf3/7 DKO or pDC:Irf7^+^ mice ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), likely due to the higher IFN-I response. Notably, at 42--72 hr post-infection, pDC:Irf7^+^ mice displayed significantly reduced levels of DENV titer and RNA in the spleen and plasma compared to Irf3/7 DKO mice ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The higher DENV levels in pDC:Irf7^+^ mice as compared to Irf3/7 DKO mice at early time points (i.e. 28 h p.i.) may reflect an enhanced recruitment of DENV-susceptible cells in the spleen of pDC:Irf7^+^ mice due to the localized pDC-induced IFN-I response ([@bib37]; [@bib39]). Our results indicate that IRF7 expression in pDCs is sufficient to control DENV through the local production of IFN-I.

![pDC:Irf7^+^mice control DENV viremia.\
DENV infection (i.v.) of mice with the indicated genotypes followed by the analysis of DENV titers/RNA in spleens (**A--B**) and plasma (**C**) collected at the indicated time points p.i. DENV RNA levels are normalized to a panel of housekeeping genes (*hprt1*, *β-actin*, and *18S* rRNA) and to exogenous RNA (*xef1A*) for spleen and plasma samples, respectively. Results are expressed as normalized Log~10~ DENV genome equivalents (GE) or Log~10~ foci forming unit (ffu)/g tissue; RNA: mean ±SD, titers: median*, n* = 5--7 mice (spleen), *n* = 5--6 mice (plasma).](elife-34273-fig4){#fig4}

Type I and type II IFN-induced ISG responses in pDC:Irf7^+^ mice {#s2-5}
----------------------------------------------------------------

To examine the downstream effector mechanisms initiated by pDC-derived IFN-I, we considered the relative contribution of lymphocyte-derived type II IFN (IFN-II) to viral clearance. Notably, an IFN-II response has been observed even in the absence of *Irf3* and *Irf7* expression in response to DENV infections, and was demonstrated to eventually control DENV infection ([@bib4]). To assess IFN-II responses, we measured *Ifng* and *Gbp2* expression, the latter being known to specifically define an IFN-II response ([@bib19]). Interestingly, *Ifng* and *Gbp2* up-regulation ([Figure 5B--C](#fig5){ref-type="fig"}) temporally correlated with the induction of IFN-I-induced ISGs in DENV-infected Irf3/7 DKO mice ([Figure 5A](#fig5){ref-type="fig"} and [Figure 4---figure supplement 1B--E](#fig4s1){ref-type="fig"}). Of note, these ISGs including *Ifit1/Usp18/Ifit3* respond more highly to IFN-I, but will still be induced to some extent by type II IFN \[([@bib4]; [@bib19]; [@bib29]) and data not shown\]. Therefore, in agreement with these prior studies, IFN-II signaling likely mediates the late induction of a larger set of ISGs observed in Irf3^-/-^/7^-/-^ mice.

![pDC:Irf7^+^mice display elevated IFN-I and accelerated IFN-II responses compared to Irf3/7 DKO mice during DENV infection.\
Mice were infected as in [Figure 4](#fig4){ref-type="fig"}. (**A--B**) Type I IFN-induced ISGs (**A**) and ISG specifically induced by type II IFN signaling (**B**). RNA levels were assessed in the spleen and normalized to housekeeping panel (*hprt1*, *β-actin*, *18S*). Transcript levels expressed as the fold change relative to uninfected mice for each genotype; geometric mean, *n* = 5--7 mice per condition, each data point corresponds to an individual mouse. (**C**) Quantification of IFNγ in spleen homogenates by ELISA; median, *n* = 5--6 mice per condition. IFNγ was undetectable in uninfected control mice.](elife-34273-fig5){#fig5}

The kinetic profile of the type II IFN response was markedly different in pDC:Irf7 +mice as compared to Irf3/7 DKO mice, with *Ifng* and *Gbp2* expression detected as early as 18 h p.i and peaking at 28 h p.i. ([Figure 5B--C](#fig5){ref-type="fig"}). This led to the compelling hypothesis that early pDC IRF7-mediated signaling accelerates the IFN-II response, which is known to be part of the eventual control of DENV in mouse models ([@bib4]; [@bib6]; [@bib40]).

Given that the ex vivo response of pDCs was biased toward IRF7-mediated IFN-I production ([Figures 1](#fig1){ref-type="fig"} and [3A--B](#fig3){ref-type="fig"}), we hypothesized that the early ISG response in pDC:Irf7^+^ mice was mediated by this pathway. To formally test the dependence of this early ISG response on IFN-I and thus IFNAR signaling, we employed an IFNAR1 blocking antibody and challenged mice with DENV. IFNAR blockade in pDC:Irf7^+^ mice abrogated this early ISG response ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) and correspondingly increased both DENV viremia in these mice, as readily observed in the spleen ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}) and to a lesser extent in the blood ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}; not significant; likely as the consequence of the limited dynamic range of DENV detection at this time point in blood). Of note, consistent with the results of [Figure 5](#fig5){ref-type="fig"}, *ISG* expression was still detected in the Irf3/7 DKO and pDC:Irf7^+^ at a later time point (72 h p.i.) ([Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}), further suggesting that the late induction of ISGs is independent of pDC IRF7-mediated IFN-I and likely induced by IFN-II. Along the same line, recent work demonstrates that IRF1-mediated IFN-II can be induced by DENV, independent of *Irf3/Irf7* expression ([@bib3]). In accordance, we showed that the IFNAR1-dependent response contributes to the control of DENV in Irf3/7 DKO mice ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}).

Together, our results demonstrated that, despite undetectable IFN-I at a systemic level, the early ISG induction and control of DENV by the pDC-IRF7-induced response relies on IFN-I/IFNAR1 signaling. Importantly, we also observed an acceleration of IFN-II signaling as a result of IRF7 expression in pDCs, temporally associated with viral control in DENV-infected pDC:Irf7^+^ mice.

Mediation of IFN-II production and viral control by NK cells {#s2-6}
------------------------------------------------------------

We next aimed at identifying the cell type(s) responsible for IFN-II production and its subsequent impact on signaling in infected pDC:Irf7^+^ mice. We observed that an elevated fraction (\~12%) of splenic NK cells produced IFNγ in DENV-infected pDC:Irf7^+^ mice ([Figure 6A](#fig6){ref-type="fig"}). For other cell types, including NKT cells, γδ-T cells, αβ-T cells and neutrophils, IFNγ+ cells represented an extremely small fraction of total splenocytes ([Figure 6A](#fig6){ref-type="fig"}, right panel and S5A-B). Interestingly, splenic, but not blood-circulating NK cells, produced IFNγ protein in response to DENV infection, consistent with the absence of upregulation of blood *Ifng* mRNA (data not shown) and limited induction of the activation marker CD69 on blood NK cells ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). This implies that NK cell response is localized to the spleen, the primary site of DENV replication. In agreement with a localized host response, we showed that the accelerated IFN-II response in DENV-infected pDC:Irf7^+^ mice was associated with an early recruitment of neutrophils to the spleen ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}) as well as maturation of monocytes (identified as Ly6C^++^/Lineage^-^ cells), as represented by upregulation of MHCII, which did not occur in Irf3/7 DKO mice ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). Of note, both cell types have been previously shown to be involved in the modulation of NK cell activation ([@bib6]; [@bib26]).

![NK cells produce IFNγ and control DENV infections in pDC:Irf7^+^mice.\
(**A**) Quantification of IFNγ^+^ cells in spleen/blood samples from DENV infected pDC:Irf7^+^ mice at 48 h p.i. by FACS. Cell subsets were identified as shown in [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}. Results presented as a percentage of each cell type (left panel) or relative to total splenocytes/PBMCs (right panel); mean ± SD, *n* = 4--6 infected, *n* = 1--2 uninfected mice per cell population. (**B--E**) pDC:Irf7^+^ mice were injected i.p. with anti-NK1.1 depleting or IgG2a control antibody and infected 24 hr later with DENV i.v.; *n* = 6--7 mice per condition. Analyses were performed at 48 h p.i. in the indicated tissues. (**B**) NK cells as a percentage of splenocytes were identified by FACS as in [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}; mean ± SD. (**C**) Log~10~ DENV genome levels; mean ± SD and Log~10~ foci forming unit (ffu)/g tissue ; median. (**D**) Quantification of IFNγ by ELISA; median. IFNγ was undetectable in uninfected control mice. (**E**) ISG RNA levels are expressed as fold change relative to uninfected IgG2a-treated control mice; geometric mean ± SD.](elife-34273-fig6){#fig6}

As NK cells were the primary producers of IFN-II ([Figure 6A](#fig6){ref-type="fig"}), we sought to identify their role during DENV infection in pDC:Irf7^+^ mice in NK cell depletion studies. An efficient depletion of NK cells (i.e. reduction by \>80% of splenic and blood NK cells, [Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) lead to a significant increase of both splenic DENV RNA and viral titers in pDC:Irf7^+^ mice ([Figure 6C](#fig6){ref-type="fig"}). This was associated with a decrease in IFNγ mRNA, IFNγ protein and IFN-II ISG signature in the spleen and plasma ([Figure 6D--E](#fig6){ref-type="fig"}), along with reduced neutrophil recruitment to the spleen and maturation of monocytes ([Figure 6---figure supplement 2B--C](#fig6s2){ref-type="fig"}). Closing the circle and establishing IFNα responses as upstream, we observed that IFN-I-induced ISG levels were not impacted by NK cell depletion in pDC:Irf7^+^ mice at 48 h p.i. ([Figure 6E](#fig6){ref-type="fig"}).

CHIKV activates a pDC IRF7-restricted response via cell-cell contact and, which controls in vivo infection {#s2-7}
----------------------------------------------------------------------------------------------------------

We extended the study to CHIKV, also a positive-sense single-stranded RNA mosquito-borne virus of major concern for human health. We tested whether pDC activation by CHIKV shares the same features as DENV, showing that indeed, human pDCs produced robust IFNα in response to CHIKV only when in contact with CHIKV-infected cells ([Figure 7A](#fig7){ref-type="fig"}). Similarly, robust IFNα levels were detected when WT mouse pDCs were co-cultured with CHIKV infected Vero cells or with syngeneic co-cultures of Irf3/7 DKO mouse embryonic fibroblasts (MEFs) ([Figure 7B--C](#fig7){ref-type="fig"}). By contrast, cell-free CHIKV and CHIKV-infected cells physically separated from pDCs did not induce IFNα secretion ([Figure 7A--B](#fig7){ref-type="fig"}). CHIKV-infected cells failed to activate pDCs deficient for *Tlr7*, whereas pDCs deficient for *Mavs* (i.e. the downstream signaling adaptor of RLR pathway) produced levels of IFNα comparable to WT pDCs ([Figure 7D](#fig7){ref-type="fig"} and data not shown). Comparable to DENV-induced responses, the sensing of CHIKV-infected cells by pDCs led to an IRF7-mediated cytokine production (IFNα), but not NF-κB-induced inflammatory cytokines (TNFα) ([Figure 7E](#fig7){ref-type="fig"}). Together, this demonstrated that, like DENV, pDC induction by CHIKV required the cell-to-cell sensing of infected cells by TLR7-induced signaling and led to an IRF7-restricted response.

![CHIKV activates a pDC IRF7-restricted response via cell-cell contact and pDC:Irf7^+^mice control CHIKV viremia.\
(**A**) Quantification of IFNα by ELISA in supernatants of human pDCs cocultured for 22--24 hr with CHIKV-infected or uninfected Huh7.5.1 cells \[seeded together or separated by a 0.4 µm transwell membrane\] or treated with CHIKV infectious supernatant (SN); median, *n = 3--5* independent experiments. (**B--D**) Quantification of IFNα levels by single molecule array (SiMoA) assay in supernatants of pDCs isolated from spleens of WT or TLR7^-/-^ mice and cocultured with Vero cells (**B, D**) or Irf3/7 DKO MEFs (**C**) for 24 hr. Cultured cells were infected or not with CHIKV-GFP, as indicated; median, *n = 3--4* independent experiments. (**E**) Quantification of IFNα and TNFα by ELISA in supernatants of human pDCs treated for 22--24 hr with CHIKV infectious supernatant (CHIKV SN), TLR7 agonists \[IMQ; 1 µg/mL and Flu; 3 × 10^3^ FFU\], or cocultured with CHIKV-infected Huh7.5.1 cells; median, *n = 4--5* independent experiments. (**F--G**) CHIKV infection subcutaneously (s.c.) of mice with the indicated genotypes followed by analysis of the survival rate (**F**) and CHIKV infectious titers in the indicated tissue homogenates (**G**); median, *n* = 7--22 mice per condition.](elife-34273-fig7){#fig7}

We thus tested whether pDC IRF7-induced responses were sufficient to protect mice from CHIKV. Mice were infected s.c. with CHIKV, and as previously reported WT mice showed no clinical symptoms, whereas Irf3/7 DKO mice rapidly succumbed to CHIKV infection ([Figure 7F](#fig7){ref-type="fig"}) ([@bib35]). By contrast, pDC:Irf7^+^ mice experienced no overt clinical symptoms with 100% of mice surviving infection ([Figure 7F](#fig7){ref-type="fig"}). Early control of viremia was improved in pDC:Irf7^+^ mice compared to Irf3/7 DKO mice, although reduced as compared to WT mice ([Figure 7G](#fig7){ref-type="fig"}). By day 7 p.i., pDC:Irf7^+^ mice had cleared CHIKV infections (data not shown). Importantly, there was differential control of CHIKV in pDC:Irf7^+^ mice depending on the tissue. The initial sites of CHIKV replication (i.e. the infection site: skin/muscle and muscle) displayed relatively higher viral titers as compared to more distal sites (i.e. the spleen and liver), where virus was barely detectable at 48 h p.i. in pDC:Irf7^+^ mice ([Figure 7G](#fig7){ref-type="fig"}). It is possible that the pDC antiviral response controls infection once virus spreads systematically, as previously proposed in the context of Herpes Simplex virus infection ([@bib43]).

We established a mouse IFNα Single Molecule Assay (SiMoA) ([@bib33]), with a quantification limit at 0.1 pg/ml (i.e. \>100 fold increased sensitivity compared to current assays, data not shown). Nonetheless plasma IFNα remained undetectable in CHIKV-infected pDC:Irf7^+^ mice at both 24 and 48 h p.i. (data not shown). Therefore, we validated the dependence on IFN-I-induced signaling for the control of CHIK by pDCs using IFNAR1 blocking antibody. IFNAR blockade in pDC:Irf7^+^ mice induced lethality and, consistently, greatly increased CHIKV viremia ([Figure 7---figure supplement 1A--B](#fig7s1){ref-type="fig"}). By contrast with results for DENV ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), IFNAR1-dependent response did contribute to the control of CHIKV in Irf3/7 DKO mice ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). This discrepancy between DENV and CHIKV infections likely reflects the greater impact of IFN-I signaling in CHIKV versus DENV infection and/or a differential contribution of the alternate IRF-mediated signal transduction. Similar to DENV, NK cell depletion in pDC:Irf7^+^ mice increased CHIKV titers ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}, \~10 fold-increase, although not statistically significant).

Together, these data indicate that IRF7 expression in pDCs is sufficient to control two genetically distant RNA viruses (CHIKV and DENV) via the local production of IFN-I and IFNγ secretion by NK cells.

Discussion {#s3}
==========

DENV and CHIKV are important mediators of human diseases, causing a significant human and economic burden worldwide. We provide compelling evidence that pDCs are a key cell type in the initiation of antiviral responses to these two distinct RNA viruses. We demonstrate that pDC activation by DENV/CHIKV is characterized by IRF7-prioritized signaling, while passively excluding NF-κB-mediated responses. Despite undetectable levels of systemic IFN-I, pDC IRF7 signaling is critical for the induction of a potent antiviral response. This might reflect a local pDC IFN-I response and is in keeping with the requirement for physical contact with infected cells to activate pDCs, in turn inducing a potent ISG response. Notably, pDC-IRF7 activation accelerates NK-mediated IFN-II induction, which assists in control of viremia.

pDCs have previously been demonstrated to be required for the control of several viral infections, including herpes simplex virus (HSV), murine hepatitis virus (MHV), murine cytomegalovirus (MCMV), vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis virus (LCMV) ([@bib41]). In contrast, others reported that pDCs are dispensable and/or do not contribute to IFN-I production in the case of certain infections, including influenza virus, respiratory syncytial virus (RSV), Newcastle disease virus (NDV) and MCMV ([@bib8]; [@bib16]; [@bib25]; [@bib27]; [@bib43]), which may be a reflection of viral replication mechanisms, inoculum size, or location ([@bib42]; [@bib43]). These observations bring the emerging concept that while antiviral response (i.e. IFN-I production) in infected cells acts as a first line defense, pDCs may serve as a failsafe, triggered upon systemic infection and therefore failure of viral control ([@bib14]; [@bib45]). This assumption is in line with the multiple inhibitory mechanisms of antiviral sensing by viral proteins expressed by infected cells ([@bib14]). Nonetheless, previous investigations have primarily demonstrated the importance of pDCs in viral control by depletion of pDCs ([@bib41]). Here, we validated a model consisting of a pDC-restricted IFN response, which offers a unique opportunity to define pDC function. This new model also permitted the study of the possible cryptic pDC-mediated control of certain infections. For instance, pDC antiviral function might be masked due to the homeostasis of the innate immunity, including an enhanced response by other cell types when pDCs are depleted.

We demonstrated that pDCs are sufficient to initiate early control of viral infections, via induction of IRF7-prone signaling. In this mouse model, the restoration of *Irf7* expression in pDCs does not reflect control under the endogenous promoter, as the *Irf7* gene is under the control of the pDC-specific *Siglech* promoter. However, *Irf7* overexpression artifacts are avoided in the pDC:IRF7+ model as *Irf7* steady-state expression is reduced under the control of the *Siglech* promoter relative to the *Irf7* promoter ([Figure 2B](#fig2){ref-type="fig"}). Furthermore, *Siglech* expression by pDCs is inversely correlated to ISG upregulation in vivo ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}), in agreement with prior study ([@bib32]). Importantly, while systemic IFN-I was not detectable in response to DENV/CHIKV infection, the pDC-IRF7 response rapidly and potently induces a broad array of ISGs in multiple organs, dependent on IFN-I signaling. Therefore, in line with our ex vivo results in this and previous studies ([@bib10]), we propose that pDCs respond in a contact-dependent manner to infected cells, and thus induce highly localized IFN-dependent responses. Importantly, this response is sufficient to impart a large-scale antiviral response, which protects from viral infections.

The engagement of TLR7/9 leading to IFN-I production and NF-κB-dependent pro-inflammatory cytokines by pDCs may affect downstream immunological parameters, such as for example, B cell differentiation induced by pDC response to influenza virus ([@bib23]). We observed that pDCs fail to respond via NF-κB-mediated inflammatory responses to DENV/CHIKV-infected cells, indicating that pDC TLR7 signaling induced by these viruses primarily leads to IRF7 induction. Consistently, on the whole-organism level, while ectopic IRF7 expression in pDCs fully restores ISG responses, NF-κB responses to DENV were absent in both pDC:Irf7^+^ and Irf3/7 DKO mice, thus underlining the importance of the IRF7 and dispensability of the NF-κB responses in pDC-mediated control of DENV and CHIKV infections. Our results also imply that NF-κB induction by these viruses in other cell types likely requires cross-talk between IRF3 and NF-κB ([@bib13]; [@bib22]).

While pDC IFN-I responses were important in early control of both DENV and CHIKV infections in vivo, substantial differences were observed in the overall outcome of infections. CHIKV infections were invariably lethal in the Irf3/7 DKO genetic background, and pDC IFN-I responses provided 100% protection to this lethal phenotype. By contrast, DENV infections were well-controlled even in Irf3/7 DKO mice by 72 h p.i. Notably, pDC IFN-I responses lead to substantial control of DENV viremia at time points intermediate between WT and Irf3/7 DKO mice (\~42--48 hr). In our study, the lethal phenotype in CHIKV infection in Irf3/7 DKO mice correlated with substantially higher viral titers, as compared to DENV levels. Interestingly, blockade of IFN-I signaling in Irf3/7 DKO mice only increased viremia in situations where lower basal viral titers were observed: for example, DENV infections in all organs, or CHIKV viral titers in the liver. We thus suggest that the persistence of IFN-I-mediated viral control under these conditions depends on IRF5 or IRF1 signaling ([@bib3]; [@bib4]; [@bib28]; [@bib34]), as control of flaviviral infections is still contingent on IFNAR signaling in the absence of *Irf3/Irf7* expression. The contribution of these alternate IRF proteins to the antiviral response may only be revealed in case of relatively low viremia.

Eventual control of DENV in the Irf3/7 DKO background depended on the induced IFNγ response ([@bib4]). In agreement, we observe an IFN-II response in DENV-infected Irf3/7 DKO mice peaking at \~42 h p.i., which is largely absent in WT mice. Importantly, the antiviral IFN-II response is accelerated in pDC:Irf7^+^ mice relative to Irf3/7 DKO mice. These pDC-regulated IFN-II responses are consistent with prior work showing a defect in type II IFN activation in a pDC-deficient mouse model ([@bib18]). We demonstrated that IFNγ production in DENV-infected pDC:Irf7^+^ mice is largely mediated by NK cells in the spleen, the primary site of DENV replication. These activated NK cells mediate downstream IFN-II responses that contribute to control of DENV viremia, in accordance with a recent report ([@bib6]). A similar decrease in viremia was observed in CHIKV-infected pDC:Irf7^+^ mice depleted of NK cells, although these results did not reach statistical significance. DENV may be more sensitive to type II IFN signaling (relative to type I IFN) compared to CHIKV, as DENV infections cause higher lethality in *Ifngr^-/-^* compared to *Ifnar^-/-^* mice, a situation that is reversed in the context of CHIKV infection ([@bib15]; [@bib40]).

Importantly, IFNγ production by NK cells was not observed in the blood, a site of low DENV viremia, likely indicating a necessity for NK cells to be closely apposed to DENV-infected cells and/or DENV-activated cells to achieve NK cell activation of IFN-II responses. We also observed an association with other immune cell parameters, including a pDC IRF7-mediated influx of neutrophils and monocyte activation in the spleens of DENV-infected mice. While some reports suggested that type I IFN directly contributes to NK cell response, NF-κB-dependent cytokines are well-known to regulate IFNγ production by NK cells ([@bib38]). Along the same lines, in vitro studies suggested that pDCs act in concert with monocytes to potentiate NK-cell-mediated IFNγ production in the context of HCV and DENV infection ([@bib6]; [@bib49]). Future studies are required to determine how DENV/CHIKV-activated pDCs can directly augment NK cell IFNγ responses, or whether pDC-produced type I IFN acts through other cell types and attendant NF-κB-dependent cytokine responses for this amplification of type II induction.

The ability to segregate NF-κB and IRF7 responses may have potential use in developing novel therapies. Notably, NF-κB-dependent cytokines have been associated with disease severity in both DENV and CHIKV infection ([@bib5]; [@bib12]). This is juxtaposed with pDC-derived IFN responses supporting viral clearance while avoiding possible inflammatory responses. As arboviral infections tend to be acute, rather than chronic diseases, this study provides an important indication of how early viral control may be mediated by one of the key drivers of the IFN response, the plasmacytoid dendritic cell.

Materials and methods {#s4}
=====================

Cells and reagents {#s4-1}
------------------

Huh7.5.1 cells ([@bib50]) (RRID:[CVCL_E049](https://scicrunch.org/resolver/CVCL_E049)), Vero cells (CLS Cat\# 605372/p622_VERO, RRID:[CVCL_0059](https://scicrunch.org/resolver/CVCL_0059)), and BHK-21 cells (ATCC Cat\# CCL-10, RRID:[CVCL_1915](https://scicrunch.org/resolver/CVCL_1915)) were maintained in DMEM (Dulbecco\'s modified Eagle medium; Life Technologies) supplemented with 10% FBS, 100 units (U)/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Life Technologies). Cells were maintained at 37°C in 5% CO~2~. MEFs were maintained in supplemented RPMI growth media. The work involved cell line, with routinely verify status for contamination (e.g. Mycoplasma).

Cell culture reagents included the TLR7 agonist (IMQ; imiquimod) and TLR7/8 agonist (R848) (Invivogen, San Diego, CA); TLR7 antagonist, IRS661 (5'-TGCTTGCAAGCTTGCAAGCA-3') synthesized on a phosphorothioate backbone (MWG Biotech, Ebersberg, Germany); TLR3 agonist (poly-I:C) (Invivogen); TLR9 agonist (CpG) (Invivogen); recombinant IFNβ (PBL Interferon Source, Piscataway, NJ). General reagents included: paraformaldehyde (PFA) and brefeldin A (BFA) (Sigma-Aldrich, St Louis, MO); Ficoll-Hypaque (GE Healthcare Life Sciences, Piscataway, NJ).

Viral stocks {#s4-2}
------------

Viral stocks of the prototypic DENV-2 strain New Guinea C (NGC) (AF038403) were produced using in vitro RNA transcripts prepared from DENV-2 infectious plasmid clone pDVWS601 plasmid ([@bib31]). Briefly, plasmid was linearized with XbaI (New England Biolabs, Ipswich, MA) and RNA transcripts were produced and purified using mMESSAGE mMACHINE T7 Kit (Ambion/Thermo Fisher Scientific, Waltham, MA). RNA transcripts were introduced into BHK-21 cells by electroporation (using 100 µg RNA to transfect 8 × 10^7^ cells, with 4 × 10^6^ cells per electroporation). Electroporation was performed in 0.4 cm cuvettes (Bio-Rad, Hercules, CA) with a Gene Pulser system (Bio-rad), using a square-wave pulse (280 V, 25 ms). Virus-containing supernatants were collected at 3--5 days post-electroporation and clarified through a 0.2 µm filter (Corning Inc, Corning, NY). Viral supernatants were concentrated by ultracentrifugation at 75000 x *g* for 2 hr at 4°C, resuspended in DMEM growth media, and frozen at −80°C until titration and/or use. Viral stocks were titered on Huh7.5.1 cells, as described below, and adjusted to 2 × 10^7^ focus-forming units (ffu)/mL.

CHIKV-21 viral stocks, used for all in vivo infections, were prepared from clinical samples ([@bib36]). Briefly, CHIKV-21 was propagated in C6/36 mosquito cells, and infectious supernatants were harvested, clarified through a 0.2 µm filter, and frozen at −80°C until titration and/or use. Recombinant CHIKV-GFP, which expresses GFP under a subgenomic promoter (CHIKV-GFP 5'), was generated from a full-length infectious cDNA clone provided by S. Higgs ([@bib46]) and was used for all CHIKV in vitro mouse studies. Briefly, CHIKV-GFP 5' plasmid was linearized with *NotI* (New England Biolabs) and RNA transcripts were produced and purified using mMESSAGE mMACHINE SP6 Kit (Ambion). RNA transcripts were introduced into BHK-21 cells by electroporation (using 1 µg RNA to transfect 5 × 10^6^ cells). Virus-containing supernatants were collected when the viral cytopathic effect reached 75% of transfected cells, clarified through a 0.2 µm filter (Corning Inc), and frozen at −80°C until titration and/or use. Viral stocks were titered on Vero cells, as described below.

DENV infectivity titers in concentrated culture supernatants or mouse organ homogenates were determined by end-point dilution using Huh 7.5.1 cells ([@bib10]). Foci forming units (ffu) were detected 72 hr after infection. Briefly, Huh7.5.1 cells were fixed with 4% PFA and permeabilized by incubation for 7 min in PBS containing 0.1% Triton. Cells were then blocked in PBS containing 3% BSA for 15 min and incubated for 1 hr with mouse anti-E glycoprotein (clone 3H5) hybridoma supernatant diluted in PBS containing 1% BSA. After three washes with PBS, cells were incubated 1 hr with secondary Alexa 555-conjugated anti-mouse antibody. Virally-infected foci of E-positive cells were determined using a Zeiss Axiovert 135 microscope.

CHIKV infectivity titers in culture supernatants or mouse organ homogenates were titrated as TCID~50~ endpoint on Vero cells using a standard procedure. Serial 10-fold dilutions of supernatants were added in six replicates in 96-well plates seeded with 10^4^ Vero cells. The cytopathic effect was scored 5 days after infection and the titers were calculated by determining the last dilution giving 50% of wells with cells displaying a cytopathic effect. Results were expressed as TCID~50~/mL.

Viral stocks of Influenza A Virus (FluAV, H1N1/New Caledonia/2006) were produced as previously described ([@bib7]) and kindly provided by Dr V. Lotteau (CIRI, Lyon, France).

Mouse models, infection and treatment {#s4-3}
-------------------------------------

All mice, previously backcrossed on a C57BL/6 background, were bred and maintained at the Institut Pasteur (Paris, France) and the Plateau de Biologie Expérimentale de la Souris (PBES, Lyon, France) with Authorization Agreement C 69 123 0303. All animal studies were performed in accordance with the European Union guidelines for approval of the protocols by the Institutional Committees on Animal Welfare of the Institut Pasteur (Paris, France, OLAW assurance \#A5476-01) and by the local ethics committee Rhône-Alpes d'Ethique pour l'Expérimentation Animale (Lyon, France, Authorization Agreement C2EA-15).

Housing conditions for mice in the PBES were as follows. Mice were housed under group conditions in individually ventilated cages, from 1 to 8 single-sex mice per cage. Specific-pathogen free (SPF) housing was maintained, with regular sanitary status testing of sentinel mice and bedding for standard mouse pathogens. Mice were fed LASQCdiet Rod16-R (Lasvendi), and temperatures were maintained at 22 ± 2°C. All mice were treatment- and drug-naive at the time of experimental manipulation. Manipulations including and following viral infections were carried out under animal BSL-3 (A3) conditions; mice were anesthetized with xylazine/ketamine (20 mg/kg and 100 mg/kg by body weight) for all A3 manipulations. Similar housing conditions were maintained at the Institut Pasteur: SPF housing, 1--5 single-sex mice per cage, and manipulations carried out under animal BSL3. All in vivo CHIKV experiments were performed at the Institut Pasteur.

*Irf3^-/-^Irf7^-/-^* double knockout (referred to as Irf3/7 DKO) mice were generated and kindly provided by Dr T. Taniguchi (University of Tokyo, Tokyo, Japan) ([@bib21]). *cardif-/-* mice were generated by Dr J. Tschopp, and *Tlr7^-/-^* mice were provided by Dr S. Akira (Osaka University, Osaka, Japan). Knock-in *Siglech^Irf7+^* mice were generated by Ozgene Pty Ltd company. Next, knock-in *Siglech^Irf7+^*mice were backcrossed onto the Irf3/7 DKO background strain for approximately 10 generations to generate *Siglech^Irf7+^*Irf3/7 DKO breeding stocks, referred to as 'Union Irf3/7 DKO'. As the *Siglech^Irf7+^* transgene replaced the endogenous *Siglech* gene, to preserve *Siglech* expression and functionality in experimental mice, 'Union Irf3/7 DKO' mice were bred with Irf3/7 DKO mice to generate *Siglech^Irf7/+^* Irf3/7 DKO ('pDC:Irf7^+^') F1 mice.

For in vivo synthetic agonist experiments, 100 µg of CpG 2216 (Invivogen, tlrl-hodna)+DOTAP (Roche) or 10 µg of poly-I:C (Invivogen, tlrl-pic) were injected intravenously (i.v.) into 8- to 12-week-old mice. For DENV in vivo experiments, 8- to 16-week-old mice were infected systemically with DENV. 1--3 litters of mice of each genotype were used per experiment; each litter was aged within 3 weeks of all others in the same experiment. Mice were randomly assorted into treatment groups by the experimenter. 2 × 10^6^ ffu of DENV was injected i.v. in the retro-orbital sinus using a 31-gauge 0.3 mL insulin syringe (Becton-Dickinson, Franklin Lakes, NJ) for all experiments. In [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, an additional group of mice were i.v. infected with 2 × 10^5^ ffu DENV, as indicated. DMEM growth media was used as a negative injection control. For CHIKV experiments, 8- to 12-week-old adult mice were infected with 10^6^ pfu (plaque-forming units) of CHIKV-21 sub-cutaneously in the right flank.

For IFNAR blocking studies, a single dose (800 µg/mouse) of anti-IFNAR1 antibody (Leinco Technologies, Fenton, MO; clone MAR1-5A3) or IgG~1~ isotype control was administered i.p. 24 hr (CHIKV) or 3 hr (DENV) before infection.

For NK cell depletion, a single dose (800 µg and 200 µg for CHIKV and DENV experiments, respectively) of α-NK1.1 antibody (BioXCell, West Lebanon, NH; clone PK136) or IgG~2A~ isotype control was injected i.p. 24 hr before infection. Mice cohorts, representing individual experiments, are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}, with mice age and sex.

Processing and analysis of mouse tissues {#s4-4}
----------------------------------------

Solid tissues were collected from mice and cell suspensions were prepared by pressing tissues through 40 µm cell strainers (Becton-Dickinson) or homogenates were prepared with the TissueLyser II (Qiagen, Hilden, Germany) or GentleMACs (Miltenyi, Bergisch-Gladbach, Germany) systems. Blood was collected by cardiac puncture (end-point) or retro-orbital bleeds and anticoagulated with ethylaminediamine tetra-acetic acid (EDTA) prior to centrifugation to collect formed elements ('blood') or plasma. For viral titers and protein (ELISA) analysis, tissues were homogenized in PBS, and for qRT-PCR analysis, tissues were homogenized in guanidinium thiocyanate citrate buffer (GTC) ([@bib11]). Virus from tissue homogenates was titrated on Vero cells (CHIKV) or Huh7.5.1 cells (DENV). Results are expressed as median culture infective dose TCID50/g (CHIKV) or ffu/g (DENV).

Cytokine measurements {#s4-5}
---------------------

IFNα/β activity from mouse tissue homogenates or plasma was quantified using Luciferase assay (Promega, Madison, WI). Briefly, type I IFN levels were determined by incubating the reporter cell line LL171 with diluted plasma or tissue homogenates (in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 50 mM β-mercaptoethanol) for 8 hr. Type I IFN activity was calculated using serial dilutions of a recombinant standard (IFNα4; PBL Interferon Source, Piscataway, NJ). Cytokine protein measurements from tissue culture supernatants, plasma, and tissue homogenates were performed by ELISA using commercially available kits: human IFNα and mouse IFNα/IFNβ (PBL Interferon Source), human TNFα and mouse TNFα/IL6/IFNγ (eBioscience/Thermo Fisher Scientific, Waltham, MA). When indicated, mouse IFNα protein levels were determined using a newly developed mouse IFNα assay on the Quanterix SiMoA platform using capture and detection antibodies obtained from eBioscience (capture: Mouse IFNα Platinum ELISA capture antibody; detection: Mouse IFNα Platinum ELISA detection antibody). Recombinant mouse IFNα2 (eBioscience) was used as a standard.

Quantitative reverse transcription-PCR (qRT-PCR) analysis {#s4-6}
---------------------------------------------------------

RNAs were isolated from plasma or tissue homogenates prepared in guanidinium thiocyanate citrate buffer (GTC; Sigma-Aldrich) by phenol/chloroform extraction procedure as previously ([@bib11]). Reverse transcription was performed using the random hexamer-primed High-Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) and quantitative PCR was carried out using the Powerup Sybr Green Master Mix (Applied Biosystems). For DENV and ISG analysis in mouse spleen, liver, and blood, absolute numbers of transcripts were generally normalized to the geometric mean of *β-actin, hprt1,* and *18S* housekeeping gene transcript numbers. For plasma samples lacking housekeeping transcripts, qRT-PCR was controlled by the addition of xenogeneic carrier RNAs encoding *xef1α* (xenopus transcription factor 1α) in vitro transcripts in plasma diluted in GTC buffer. The sequences of the primers used in analysis are described in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Isolation of pDCs and ex vivo coculture experiments {#s4-7}
---------------------------------------------------

Mouse pDCs were isolated from male and female mice from 8 to 22 weeks of age, of the indicated genotypes. pDCs were isolated from splenocytes/bone marrow via negative selection using the pDC isolation kit II (Miltenyi) or from bone marrow via positive selection using PDCA1-biotin antibody (Miltenyi) followed by anti-biotin microbead (Miltenyi) selection. Human pDCs were isolated from PBMCs derived from leukapheresis of healthy adult human volunteers, obtained according to procedures approved by the 'Etablissement Français du sang' (EFS) Committee. PBMCs were isolated using Ficoll-Hypaque density centrifugation. Human pDCs were positively selected from PBMCs using BDCA-4-magnetic beads (Miltenyi), as we previously reported ([@bib10]).

After isolation, pDCs were cultured with Vero, Huh7.5.1, BHK-21, or Irf3/7 DKO primary MEF cells in RPMI cell growth media (10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, non-essential amino acids, 1 mM sodium pyruvate and 0.05 mM β-mercaptoethanol) in 96-well round bottom plates at 37°C, as previously described ([@bib10]), using 8 × 10^4^ mouse pDCs when cocultured or 1 × 10^4^ human pDCs. Cocultured cells were either naive, previously infected or infected 24 hr post-coculture, using a multiplicity of infection of 5 and 2 for CHIKV and DENV, respectively. Cell culture supernatants were collected at 22--24 hr after the beginning of coculture with the infected cells.

Antibodies, flow cytometry and cell sorting {#s4-8}
-------------------------------------------

For flow cytometry, FACs sorting, and magnetic cell isolation, biotin, BV421, Pacific Blue, FITC, PE, PE-Cy7, APC, AlexaFluor-647, AlexaFluor-700, APC-eFluor780 or PerCP-Cy5.5 conjugates of the following anti-mouse antibodies were used (clone in parentheses): Siglec-H (440 c), B220 (RA3-6B2), CD11c (N418), CD11b (M1/70), CD8a (53--6.7), CD2 (RM2-5), CD19 (1D3), CD4 (GK1.5), CD3 (17A2, 500A2), NK1.1 (PK136), CD69 (H1.2F3), Ly6C (HK1.4), Ly6G (1A8), PDCA-1 (JF05-1C2.4.1), CD25 (3C7), CD49b (DX5, HMα2), TER-119 (TER-119), TCR-γδ (UC7-13D5), TCR-β (H57-597), IFNγ (XMG1.2), IRF7 (MNGPKL) (Miltenyi; eBioscience; Becton-Dickinson; Biolegend, San Diego, CA). Dylight-405 and Dylight-680 streptavidin conjugates (Life Technologies) were used to detect biotinylated antibodies.

Intracellular and extracellular staining was performed as follows. Isolated splenocytes and blood cells were depleted for erythrocytes by incubation at room temperature in red blood cell lysis buffer (1.5 M NH~4~Cl, 100 mM NaHCO~3~, 10 mM Na~2~EDTA, pH 7.4) and cells were washed in FACS buffer (PBS + 2 mM EDTA +5% FCS). For extracellular staining, cell surface marker staining was performed with antibodies diluted in FACS buffer, followed by fixation using 4% PFA. For intracellular staining, cells were incubated for 3 hr at 37°C in RPMI cell growth media + 10 µg/mL BFA, and cell surface marker staining was performed in FACS Buffer +10 µg/mL BFA. Fixation, permeabilization, and intracellular staining (IFNγ) was performed using the Cytofix/Cytoperm kit (Becton-Dickinson).

Statistical analysis {#s4-9}
--------------------

Statistical analysis was performed using PRISM v7.03 software (Graphpad, La Jolla, CA); only biological replicates representing separate mice and/or human donors are presented as data herein. Technical replicates, representing repeated measurements or treatments of the same cellular populations, were averaged prior to analysis. Mouse experiments were designed to detect a two-fold difference in means of parametric data at 95% confidence (*n* ≥ 4 per condition, assumed CV = 0.3); however, larger sample sizes were used as litter numbers permitted. Viral titers and cytokine levels were considered non-parametric due to the presence of many data points at the assay detection limits; therefore, non-parametric Kruskal-Wallis tests with Dunn's multiple comparison corrections were performed on this data. Viral RNA levels and transcript fold changes, as log-normal parametric data, were log-transformed prior to analysis using parametric tests. Kinetic analyses of ex vivo pDC cytokines ([Figure 1A--B](#fig1){ref-type="fig"}) were analyzed by one-way ANOVA parametric tests of AUC (area under the curve). Parametric tests were: unpaired Student's t test for comparisons of two conditions, one- or two-way ANOVA with a Holm-Sidak multiple comparison correction for comparison of multiple conditions. Statistical analysis of survival curves was performed using log-rank (Mantel-Cox) tests.
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Animal experimentation: All mice were bred and maintained at the Institut Pasteur (Paris, France) and the Plateau de Biologie Expérimentale de la Souris (PBES, Lyon, France) with Authorization Agreement C 69 123 0303. All animal studies were performed in accordance with the European Union guidelines for approval of the protocols by the Institutional Committees on Animal Welfare of the Institut Pasteur (Paris, France, OLAW assurance \#A5476-01) and by the local ethics committee Rhône-Alpes d\'Ethique pour l\'Expérimentation Animale (Lyon, France, Authorization Agreement C2EA-15). Housing conditions for mice in the PBES were as follows. Mice were housed under group conditions in individually-ventilated cages, from 1-8 single-sex mice per cage. Specific-pathogen free (SPF) housing was maintained, with regular sanitary status testing of sentinel mice and bedding for standard mouse pathogens. Mice were fed LASQCdiet® Rod16-R (Lasvendi). All mice were treatment- and drug-naïve at the time of experimental manipulation. Manipulations including and following viral infections were carried out under animal BSL-3 (A3) conditions; mice were anesthetized with xylazine/ketamine (20 mg/kg and 100 mg/kg by body weight) for all A3 manipulations. Similar housing conditions were maintained at the Institut Pasteur: SPF housing, 1-5 single-sex mice per cage, and manipulations carried out under animal BSL3. All in vivo CHIKV experiments were performed at the Institut Pasteur.
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###### Mouse cohorts used for *in viv*o studies.

Mouse genotype, age, sex, and number are provided for the *in vivo* experiments performed in [Figures 3](#fig3){ref-type="fig"}--[7](#fig7){ref-type="fig"} and supplements.
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###### Primer sets used in quantitative RT-PCR.

The primer sets used to amplify genes from cDNA for expression analysis are provided.
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All data generated or analysed during this study are included in the manuscript and supporting files.
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Decision letter

Yokoyama

Wayne M

Reviewing Editor

Howard Hughes Medical Institute, Washington University School of Medicine

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Plasmacytoid Dendritic Cells Control Dengue and Chikungunya Virus Infections via IRF7-regulated interferon responses\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wenhui Li as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Jonathan J Miner (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript was reviewed by two experts in the field and a member of the Board of Reviewing Editors (BRE). All reviewers felt the manuscript has the potential to be an important contribution to the literature. However, the reviewers had several comments that need to be addressed before the paper can be considered further for publication in *eLife*. While the complete, unedited reviews are given below, the reviewers and the BRE member have come up with a consensus statement that outlines the priority issues that need to be addressed in a revised manuscript.

1\) While describing experiments with two viruses is a strength of the manuscript, the manuscript would be improved by focusing on one virus throughout the manuscript. Experiments addressing key points could be shown for the other virus but the way that it is presented, going back and forth between the two viruses throughout the paper is confusing and distracting, especially since there are different gene expression signatures between the viruses. This approach would help in condensing and focusing the Introduction as well.

2\) Some of the experiments appear to lack sufficient data points to allow for appropriate statistical analysis, calling into question the validity of the interpretations.

In a revised manuscript, the authors need to address all comments of the reviewers as stated in their complete reviews as indicated below.

*Reviewer \#1:*

This is a very interesting manuscript, and I think it would be an outstanding addition to the literature. The authors demonstrate that IRF7 expression in pDCs is sufficient to restrict CHIKV and DENV infection in mice. I think the most important contribution of this paper is the discovery that an IRF7-mediated anti-viral response in pDCs is sufficient to restrict CHIKV and DENV infection in vivo.

I do not have any problem with the data, but I do have two major questions that center on methods and the Discussion.

1\) In SiglecH IRF7/IRF7 mice, expression of IRF7 is not controlled by the IRF7 promoter. SiglecH promoter-controlled expression of IRF7 in pDCs may have very distinct effects from regulated expression of IRF7 by the IRF7 promoter. The manuscript would be strengthened if the authors could discuss limitations associated with this particular issue.

2\) If I understood the methods correctly, mice of different genotypes appear to have been infected at an age range of up to 3 weeks. This difference in ages can make a substantial impact on vulnerability to viral infections (for example, during West Nile virus infection, infection at age 5 weeks results in \~90% lethality, whereas infection at 8 weeks results in \~75% lethality.) Instead of providing a range of ages, could the authors be more precise about the age of infected mice of each genotype?

*Reviewer \#2:*

The manuscript by Webster et al. describes the assessment of pDCs in two different arboviruses: dengue (DENV) and chikungunya (CHIKV) through the role of IRF7-driven IFN production. In general, the study is technically well-conducted and to decipher the immunomodulatory functions of pDCs in arbovirus sensing, authors generated the pDC:Irf7^+^ mouse model in C57BL/6 mice in order to restrict the role of IRF7 to pDCs. A wealth of data was produced that showed an indirect role for pDC IRF7-signalling in both viruses. However, the authors should consider removing one virus to streamline the datasets to improve clarity. As it stand, the datasets are scattered and all over the place due to the different viral characteristics of the 2 viruses. Specific comments below:

1\) Introduction -- although well-written, the Introduction is too long and clumsy. This is expected as due to the description of 2 viruses. Both are different with specific characteristics. It could be significantly shortened and more focused.

2\) Figures 1 and 2 on cell-cell sensing of DENV and CHIKV -- the infection conditions and viral kinetics between these 2 viruses are very different. Where infections conducted using the same batch of cells? Nonetheless, have the authors done a direct comparison between DENV and CHIKV in terms of fold change in IFNa levels? At 24h, 1 out of 3 replicates had TNFa levels of closed to 100 pg/ml. Is this sufficient to conclude that there was minimal or no TNFa production? In general, there are insufficient replicates with no statistics done.

3\) Figures 3 to 7 on in vivo responses of DENV and CHIKV in pDC:Irf7^+^ mice -- a mix of DENV and CHIKV datasets are distributed between the main and supplementary figures. Insufficient data points for proper statistics to be performed that weakened the study. Have the authors considered putting the levels of ISGs from 2 different types of infections together as a comparative? This will be more insightful to understand the similar and different mechanistic effects of virus sensing on IRF signalling on pDCs. Heat-maps provided in Figure 4 and Figure 3---figure supplement 1 suggest different signatures in terms of fold change. Otherwise, the rationale of combining 2 viruses into 1 story is not compelling.

10.7554/eLife.34273.022

Author response

> This manuscript was reviewed by two experts in the field and a member of the Board of Reviewing Editors (BRE). All reviewers felt the manuscript has the potential to be an important contribution to the literature. However, the reviewers had several comments that need to be addressed before the paper can be considered further for publication in eLife. While the complete, unedited reviews are given below, the reviewers and the BRE member have come up with a consensus statement that outlines the priority issues that need to be addressed in a revised manuscript.
>
> 1\) While describing experiments with two viruses is a strength of the manuscript, the manuscript would be improved by focusing on one virus throughout the manuscript. Experiments addressing key points could be shown for the other virus but the way that it is presented, going back and forth between the two viruses throughout the paper is confusing and distracting, especially since there are different gene expression signatures between the viruses. This approach would help in condensing and focusing the Introduction as well.

We thank the Editor for highlighting that comparing the two viruses is a strength of the study. To improve the flow of the manuscript, the text and figures were reorganized to reflect the primary focus of the manuscript on dengue virus and a corroborating figure (New Figure 7) presenting the extension of these findings in the context of chikungunya virus.

Here is the list of the changes made in the set of Figures:

\- New Figure 1: previous Figure 2B-E (DENV) and the next figures are shifted as follows: new Figure 2 include results of previous Figure 3; new Figure 3=previous 4; new Figure 4=previous 5, etc.

\- New Figure 7 (CHIKV data): including results of previous Figures 1A, 1B, 2A, 5A and 5B.

\- New Figure---figure supplement 1 (CHKV data): including results of previous Figures 1C, 1D, S4E, S4F, 7G.

The text has been edited accordingly, with a condensed Introduction.

> 2\) Some of the experiments appear to lack sufficient data points to allow for appropriate statistical analysis, calling into question the validity of the interpretations.

This point was addressed by performing additional experiments and statistical analyses for the results of new Figure 1A-B, Figure 2B-C, Figure 3A-B, Figure 6B-E, Figure 6---figure supplement 2 and Figure 7A-E.

> In a revised manuscript, the authors need to address all comments of the reviewers as stated in their complete reviews as indicated below.
>
> Reviewer \#1:
>
> This is a very interesting manuscript, and I think it would be an outstanding addition to the literature. The authors demonstrate that IRF7 expression in pDCs is sufficient to restrict CHIKV and DENV infection in mice. I think the most important contribution of this paper is the discovery that an IRF7-mediated anti-viral response in pDCs is sufficient to restrict CHIKV and DENV infection in vivo.
>
> I do not have any problem with the data, but I do have two major questions that center on methods and the Discussion.
>
> 1\) In SiglecH IRF7/IRF7 mice, expression of IRF7 is not controlled by the IRF7 promoter. SiglecH promoter-controlled expression of IRF7 in pDCs may have very distinct effects from regulated expression of IRF7 by the IRF7 promoter. The manuscript would be strengthened if the authors could discuss limitations associated with this particular issue.

We thank the reviewer for the suggestion. This aspect is now discussed see text:

"In this mouse model, the restoration of Irf7 expression in pDCs does not reflect control under the endogenous promoter, as the Irf7 gene is under the control of the pDC-specific Siglech promoter. \[...\] Furthermore, Siglech expression by pDCs is inversely correlated to ISG upregulation in vivo (Figure 4---figure supplement 1E), in agreement with prior study (Puttur et al., 2013)."

> 2\) If I understood the methods correctly, mice of different genotypes appear to have been infected at an age range of up to 3 weeks. This difference in ages can make a substantial impact on vulnerability to viral infections (for example, during West Nile virus infection, infection at age 5 weeks results in \~90% lethality, whereas infection at 8 weeks results in \~75% lethality.) Instead of providing a range of ages, could the authors be more precise about the age of infected mice of each genotype?

We now provide a table with the list of the age and sex of mice used for all the experiments, as well as the number of individual cohorts used for each genotype/time point in these studies (new Supplementary file 1). Mice of different genotypes within cohorts (or across cohorts when those comparisons were performed) were within 3 weeks of age of each other. We did not observe any apparent differences according to the age of the mice.

> Reviewer \#2:
>
> The manuscript by Webster et al. describes the assessment of pDCs in two different arboviruses: dengue (DENV) and chikungunya (CHIKV) through the role of IRF7-driven IFN production. In general, the study is technically well-conducted and to decipher the immunomodulatory functions of pDCs in arbovirus sensing, authors generated the pDC:Irf7^+^ mouse model in C57BL/6 mice in order to restrict the role of IRF7 to pDCs. A wealth of data was produced that showed an indirect role for pDC IRF7-signalling in both viruses. However, the authors should consider removing one virus to streamline the datasets to improve clarity. As it stand, the datasets are scattered and all over the place due to the different viral characteristics of the 2 viruses. Specific comments below:
>
> 1\) Introduction -- although well-written, the Introduction is too long and clumsy. This is expected as due to the description of 2 viruses. Both are different with specific characteristics. It could be significantly shortened and more focused.

As above-mentioned in the response to the Editor, the text and figures were considerably reorganized, focusing first on dengue virus and with the key findings on CHIKV infection separated into a new Figure 7 and related new Figure 7---figure supplement 1. The Introduction has been focused accordingly.

> 2\) Figures 1 and 2 on cell-cell sensing of DENV and CHIKV -- the infection conditions and viral kinetics between these 2 viruses are very different. Where infections conducted using the same batch of cells? Nonetheless, have the authors done a direct comparison between DENV and CHIKV in terms of fold change in IFNa levels? At 24h, 1 out of 3 replicates had TNFa levels of closed to 100 pg/ml. Is this sufficient to conclude that there was minimal or no TNFa production? In general, there are insufficient replicates with no statistics done.

The reviewer is correct that some infection conditions and viral kinetics are different between DENV/CHIKV. For example, BHK21 cells were used as DENV-infected cells (Figure 1A-B) and Huh7.5.1 cells were used as CHIKV-infected cells (Figure 7E) in cocultures with human pDCs. However, the xenogeneic nature of the DENV cocultures was purposeful, to allow qPCR analysis specifically of the human pDCs rather than DENVinfected cells by using species-specific primer sets (Figure 1---figure supplement 1D). Importantly, this manuscript and prior work (Decembre et al., 2014) have demonstrated that pDC responses are robust and not dependent on specific coculture conditions (e.g., tissue origin and/or species of the virally-infected cells).

Additionally, as suggested by this reviewer, we performed a direct comparison of pDC response to cells infected by either DENV or CHIKV. As shown in [Author response image 1](#respfig1){ref-type="fig"}, the IFNα levels are within the same range.

![Quantification of IFNα by ELISA in supernatants of human pDCs cocultured with Huh7.5.1 cells infected by either CHIKV or DENV, or uninfected.\
Cells were infected 48 hours prior to cocultures.](elife-34273-resp-fig1){#respfig1}

Further, we performed new additional experiments and statistical analyses for ex vivo studies of TNFα versus IFNα production as well as other ex vivo studies, now included in:

\- new Figure 1 panels A and B

\- new Figure 3 panels A and B

These panels include additional new results.

For the comparison of pDC cytokine production across mouse genotypes, rank-order statistical analysis (e.g., Kruskal-Wallis) was necessary due to many non-parametric data points at the limit of detection of the ELISA assay. Strong statistically significant differences were observed when comparing IFNα secretion between only pDC:IRF7^+^ and Irf3^-/-^/7^-/-^ pDCs in response to various TLR7/8 stimuli. However, the inclusion of WT pDCs, with greater IFNα secretion in these analyses, distorted the rank orders in a fashion that very large sample sizes would be necessary to ascertain statistical differences between pDC:IRF7^+^ and Irf3^-/-^/7^-/-^ pDCs (n\>8 independent pDC isolations). We believe it is more informative to include data from WT pDCs in these analyses, even at the expense of losing statistical power for the pDC:IRF7^+^ versus Irf3^-/-^/7^-/-^ comparison, especially as the pattern of IFNα secretion was broadly similar across a range of TLR7/8 stimuli (DENV, Flu, IMQ, R848).

We have now included new Figure 7 panels A-to-E.

> 3\) Figures 3 to 7 on in vivo responses of DENV and CHIKV in pDC:Irf7^+^ mice -- a mix of DENV and CHIKV datasets are distributed between the main and supplementary figures. Insufficient data points for proper statistics to be performed that weakened the study. Have the authors considered putting the levels of ISGs from 2 different types of infections together as a comparative? This will be more insightful to understand the similar and different mechanistic effects of virus sensing on IRF signalling on pDCs. Heat-maps provided in Figure 4 and Figure 3---figure supplement 1 suggest different signatures in terms of fold change. Otherwise, the rationale of combining 2 viruses into 1 story is not compelling.

As above-mentioned, the text and figures are now deeply reorganized to separate DENV and CHIKV. In vivo results now include additional data and statistical analysis:

\- in new Figure 2 panels B and C, with inclusion of new data;

\- in new Figure 6 panels B-to-E and corresponding Figure 6---figure supplement 2, with inclusion of new mouse cohort.

The comparison for ISGs would be interesting but the study for CHIKV infection was not designed for this type of analysis, so none of these samples or data are available. We agree that, moving forward, extending these types of analyses of IFN signaling to viruses other than DENV will be quite interesting in the future.

The heat-maps from new Figure 3E-G (previous Figure 4) and Figure 3---figure supplement 1 are indeed presented differently: results in new Figure 3E-G are expressed as Z-score and are magnitude-independent while the fold change in Figure 3---figure supplement 1 provides information on the magnitude of the change. The reasoning for these distinct displays was to show the general pattern of ISG/NF-κB gene change in Figure 3E-G, while providing the data on the magnitude of the response for those interested in Figure 3---figure supplement 1. This has been clarified in the text, as follows: "(Figure 3E-G, expressed as magnitude-independent Z score, and Figure 3---figure supplement 1, expressed as magnitude-dependent fold-change)".

[^1]: These authors contributed equally to this work.
